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Abstract
Osteoporosis, the most prevalent metabolic bone disease among older people, increases risk for low trauma hip fractures
(HF) that are associated with high morbidity and mortality. Hip bone size (BS) has been identified as one of the key
measurable risk factors for HF. Although hip BS is highly genetically determined, genetic factors underlying the trait are still
poorly defined. Here, we performed the first genome-wide association study (GWAS) of hip BS interrogating ,380,000 SNPs
on the Affymetrix platform in 1,000 homogeneous unrelated Caucasian subjects, including 501 females and 499 males. We
identified a gene, PLCL1 (phospholipase c-like 1), that had four SNPs associated with hip BS at, or approaching, a genome-
wide significance level in our female subjects; the most significant SNP, rs7595412, achieved a p value of 3.72610
27. The
gene’s importance to hip BS was replicated using the Illumina genotyping platform in an independent UK cohort containing
1,216 Caucasian females. Two SNPs of the PLCL1 gene, rs892515 and rs9789480, surrounded by the four SNPs identified in
our GWAS, achieved p values of 8.62610
23 and 2.44610
23, respectively, for association with hip BS. Imputation analyses on
our GWAS and the UK samples further confirmed the replication signals; eight SNPs of the gene achieved combined
imputed p values,10
25 in the two samples. The PLCL1 gene’s relevance to HF was also observed in a Chinese sample
containing 403 females, including 266 with HF and 177 control subjects. A SNP of the PLCL1 gene, rs3771362 that is only
,0.6 kb apart from the most significant SNP detected in our GWAS (rs7595412), achieved a p value of 7.66610
23 (odds
ratio=0.26) for association with HF. Additional biological support for the role of PLCL1 in BS comes from previous
demonstrations that the PLCL1 protein inhibits IP3 (inositol 1,4,5-trisphosphate)-mediated calcium signaling, an important
pathway regulating mechanical sensing of bone cells. Our findings suggest that PLCL1 is a novel gene associated with
variation in hip BS, and provide new insights into the pathogenesis of HF.
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Introduction
Osteoporosis is a serious public health problem in the elderly,
leading to low trauma hip fractures (HF) that are associated with
high morbidity and mortality. Hip bone size (BS) is one of the
major parameters for hip bone quality and strength, and it has
been shown that abnormal hip BS contributes significantly to the
pathogenesis of HF [1,2]. Consequently, hip BS has been
identified as an important risk factor for HF.
Genetic factors play an important role in BS variation. One
recent study demonstrated that the heritability of BS can reach as
high as 75% [3], but specific genes underlying variation of BS,
particularly hip BS, are still largely unknown. Only a limited
number of association studies have been performed on hip BS to
date, usually without full replication. They have implicated a few
interesting candidate genes, such as VDR [4], COL1A2 [5] and
CYP17 [6]. However each of these studies focused on genes with
known significance in bone biology and, consequently, was not
PLoS ONE | www.plosone.org 1 September 2008 | Volume 3 | Issue 9 | e3160designed to identify potentially novel genes/regulatory mecha-
nisms underlying hip BS.
A powerful strategy for identifying new genes associated with
hip BS is genome-wide association studies (GWAS) that take
advantage of the rapid development of high throughput SNP
genotyping platforms combined with increasing knowledge of
linkage equilibrium (LD) patterns in humans. The GWAS
approach has demonstrated its great power to identify novel
genes for human complex diseases/traits [7–11], using currently
available high SNP density platforms that permit detection of
culprit DNA changes within a narrow genomic region.
Here we conducted the first GWAS to search for novel genes
underlying hip BS variation. Using Affymetrix 500 K arrays, we
successfully genotyped and analyzed a total of ,380,000 SNPs in
1,000 unrelated Caucasians, including 501 females and 499 males.
We identified a gene, PLCL1, that was associated with hip BS at
the genome-wide significance level in female subjects. The gene’s
association with hip BS was replicated in an independent cohort
from UK containing 1,216 Caucasian women. More importantly,
the gene’s relevance to HF was observed in a Chinese sample
containing 266 HF and 177 control subjects. (The subject
characteristics of the cohorts used are detailed in Materials and
Methods section and presented in Table 1.) Our findings strongly
support the importance of the PLCL1 gene to hip BS, and to the
pathogenesis of HF.
Results
GWAS findings
We performed genome-wide genotypic association analyses for
hip BS in our GWAS sample containing 1,000 subjects, but did not
detect any SNP that passed the genome-wide significance threshold
of 4.2610
27 in the total sample. We then proceeded with gender-
specific association analyses and identified a SNP, rs7595412, that
achieved a genome-wide significant p value of 3.72610
27 in our
femalesubjects.Rs7595412isinintron3ofthePLCL1gene(Table2
and Figure 1). Carriers of the major A allele of this SNP have on
average ,5c m
2 or ,17% larger hip BS than non-carriers. In
addition to the above SNP, three other SNPs in or near the PLCL1
gene (rs4850820, rs10180112 and rs4850833) also achieved p values
approaching genome-wide significance (p=4.61610
26, 4.73610
26
and7.04610
26,respectively;Table2).Ofthesethree SNPs,twoare
in intron 5 and one is ,72 kb downstream from the gene (Table 2
and Figure 1). Altogether these four SNPs span a region of
,123 kb, and are in strong LD (Figure 1). Additional details about
these four SNPs are presented in Table 2 and Figure 1.
Table 1. Basic characteristics of study subjects.
Traits GWAS sample (N=1,000)
UK replication sample
(Female, N=1,216) Chinese HF sample (Female, N=403)
Female (N=501) Male (N=499) Case (N=226) Control (N=177)
Age (years) 50.1 (17.7) 50.5 (18.9) 48.7 (11.8) 72.1 (8.9) 67.7 (6.3)
Height (cm) 163.8 (6.5) 177.8 (7.0) 162.1 (6.2) 157.8 (4.7) 153.2 (6.7)
Weight (kg) 71.2 (15.9) 89.0 (14.9) 67.0 (12.7) 55.6 (11.2) 56.8 (10.1)
Hip BS (cm
2) 34.2 (3.4) 44.7 (4.5) 33.6 (3.9) 22
Note: Presented as means (SD).
doi:10.1371/journal.pone.0003160.t001
Table 2. Information for SNPs of the PLCL1 gene associated with hip BS or HF.
SNP Name Position Role Allele
1 MAF
2 MAF
3 P Value/OR
4
GWAS sample (association with hip BS)
rs7595412 Chr2: 198670488 Intron 3 A/G 0.112 0.117 3.72610
27
rs4850820 Chr2: 198690456 Intron 5 G/C 0.124 0.117 4.61610
26
rs10180112 Chr2: 198691103 Intron 5 G/C 0.125 0.117 4.73610
26
rs4850833 Chr2: 198793906 downstream G/A 0.139 0.125 7.04610
26
UK replication sample (association with hip BS)
rs892515 Chr2: 198686066 Intron 5 C/T 0.309 0.350 8.62610
23
rs9789480 Chr2: 198755871 downstream C/A 0.279 0.283 2.44610
23
Chinese HF sample (association with HF)
rs3771362 Chr2:198671076 Intron 3 C/T 0.214 0.267 7.66610
23
0.26 (0.09–0.75)
Note:
1The second allele represents the minor allele of each locus.
2Minor allele frequency calculated in our own Caucasian/Chinese sample.
3Minor allele frequency reported for Caucasians in the public database of HapMap CEU, except for the MAF of rs3771362 that is from HapMap HCB for Chinese.
4Odds ratio with 95% confidence interval for the SNP, rs3771362, is for the minor allele.
doi:10.1371/journal.pone.0003160.t002
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findings, we present in Appendix S1 the most significant 30 SNPs
detected genome-wide in the total sample as well as in each gender
subgroup.
Replication of the PLCL1 gene’s association with BS in
the UK sample
In the UK replication sample, using a different genotyping
platform, we also observed strong association signals for the PLCL1
gene with hip BS. We compared the association signals of our
GWAS with those achieved in the GWAS performed in the UK
cohort. The SNPs/genes that achieved p values less than 0.01 in
our GWAS were checked for p values achieved in the UK cohort,
and vice versa for those SNPs/genes that achieved p values less
than 0.01 in the UK cohort. As a result, the only gene that showed
significant in silico replication signals is the PLCL1 gene that had
four SNPs associated with hip BS in our GWAS (p,10
25) (Table 2)
and two SNPs associated with hip BS in the UK cohort (p,0.01)
(Table 2).
A SNP in intron 5 of the PLCL1 gene, rs892515, achieved a p
value of 8.62610
23 for association with hip BS in the UK sample.
That SNP is located between the most significant and the 2
nd most
significant SNPs of the PLCL1 gene (i.e., rs7595412 and rs4850820,
respectively) identified in our GWAS. The SNP rs892515 is
separated from rs7595412 and rs4850820 by ,15 kb and ,4k b ,
respectively (Table 2 and Figure 1). Another SNP, rs9789480,
located ,35 kb downstream from the PLCL1 gene, achieved a p
value of 2.44610
23 in the UK sample. That SNP is positioned
betweentwootherinterestingSNPs(i.e.,rs10180112andrs4850833)
of the PLCL1 gene identified in our GWAS (,64 kb away from the
former and ,38 kb away from the latter SNP) (Table 2 and
Figure 1). The haplotype formed by the two SNPs identified in the
UKsamplealsoachieved apvalueof1.55610
23forassociationwith
hip BS (Figure 1). Additional details about these two SNPs and their
relative position in relation to the four SNPs identified in our GWAS
is shown in Table 2 and Figure 1. As shown in Figure 1, rs892515
and rs9789480 have strong LD with each other, but weak LD with
the four SNPs identified in our GWAS, even though these six SNPs
are physically intermingled together.
Figure 1. Association signals of PLCL1 gene in GWAS and UK replication samples. Note: 1. This haplotype block map was constructed using
the most recent SNP genotype data (HapMap Data Rel 23a/phaseII Mar 08, on NCBI B36 assembly, dbSNP b126) from HapMap (www.hapmap.org),
showing pairwise LD in r
2. 2. The black bar represents the association signal (p=1.55610
23) achieved in the UK replication sample for the haplotype
block formed by the two SNPs, rs892515 and rs9789480.
doi:10.1371/journal.pone.0003160.g001
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As only ,15% of SNPs overlap between the genotyping
platform for our GWAS sample (i.e., Affymetrix) and that for the
UK replication sample (i.e., Illumina), to better compare the
association signals between the two samples, we imputed a
common set of dense SNP markers covering the PLCL1 gene and
its vicinity. The imputed association signals for the whole span of
the gene are plotted in Figure 2. According to the imputation
results, eight SNP markers achieved p values less than 1610
26,
and five additional SNP markers achieved p values less than
1610
25 in our GWAS sample. In the UK replication sample,
more than ten SNP markers achieved p values less than 0.01. More
importantly, the strongest association signals for both samples
overlap nicely in a region covering ,3/4 length of intron 5 and
extending immediately downstream from the gene (shown in the
Figure 2 as the region between the two dashed vertical lines).
Figure 3 zooms in on the region between the two dashed lines,
highlighted in Figure 2, to examine this region more closely; only
those SNPs that achieved p values less than 1610
25 in the GWAS
sample, and those that achieved p values less than 0.05 in the UK
sample, are shown. Detailed information for some of the plotted
SNPs is presented in Table 3. A noticeable region in intron 5 with
strong replication signals is highlighted in Figure 3 within the
dashed rectangle (also designated ‘‘Region I’’ in Table 3). That
region is less than 6 kb and contains nine significant SNP markers,
according to imputation results. In that small region, two SNPs
achieved genome-wide significant p values (p,4.2610
27) and two
achieved p values less than 1610
25 in the GWAS sample; four
other SNPs in this region achieved p values less than 0.01 in the
UK sample. Another interesting region in intron 5 (demarcated in
Figure 3 as inside brackets, and designated ‘‘Region II’’ in Table 3)
is flanked by two SNPs, rs989056 and rs10168722, both of which
achieved genome-wide significant p values (p,4.2610
27) in the
GWAS sample. In the UK sample, this region of ,11 kb
contained three SNPs with p values less than 0.01 and two
additional SNPs with p values less than 0.05.
Using Fisher’s method [12], we combined the imputed p values
achieved in the two samples. We found that eight SNPs of the
PLCL1 gene achieved combined imputed p values less than 10
25,
another five SNPs achieved combined p values less than 10
24, and
fifteen more SNPs achieved combined p values less than 0.01.
These SNPs are mainly those as shown in Figure 3. Additional
details of these SNPs are presented in Table 4.
PLCL1 gene’s importance to HF
To further examine the PLCL1 gene’s importance to HF, we
took advantage of a recently completed GWAS of HF in Chinese
(containing 403 females and 297 males). We re-analyzed SNPs of
the PLCL1 gene, used for the previous GWAS, for association with
HF in Chinese female subjects. The SNP that achieved the most
significant p value in our GWAS in Caucasians (rs7595412) is not
polymorphic in Chinese. However, a neighboring SNP,
rs3771362, that is only ,0.6 kb from rs7595412 achieved a p
value of 7.66610
23 for association with HF in the Chinese
females, with an odds ratio (95% CI) of 0.26 (0.09–0.75) (Table 2).
The SNP was not found to be associated with HF in the male
subjects of the Chinese sample.
PLCL1 gene’s importance to other relevant phenotypes
In the female subjects of our GWAS cohort, we also analyzed
the PLCL1 gene’s importance to other phenotypes relevant to
osteoporosis, including hip and spine BMD, spine BS and height.
The SNPs under analysis were the four SNPs of the gene that
achieved the most significant results for association with hip BS in
the female subjects of our GWAS cohort (Table 2).
We did not find significant association of the SNPs with hip
and spine BMD and with height. However, we found
marginally significant association of the SNPs with spine BS.
The p values achieved by the SNPs (rs7595412, rs4850820,
rs10180112 and rs4850833) are 0.048, 0.092, 0.092, and 0.056,
respectively.
Figure 2. Imputation results for the PLCL1 gene in our GWAS and UK replication samples.
doi:10.1371/journal.pone.0003160.g002
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Since osteoporosis incidence was found to be inversely
associated with BMI [13], we also examined the influence of
BMI on the PLCL1 gene’s association with hip BS. In our GWAS
cohort (female subjects), BMI appears to have some effects on the
PLCL1 gene’s association with hip BS. Adjusting hip BS with BMI
Figure 3. Association results imputed for intron 5 and the region immediately downstream from the PLCL1 gene.
doi:10.1371/journal.pone.0003160.g003
Table 3. Major imputation results for intron 5 of the PLCL1 gene.
Region GWAS Sample Replication Sample
SNP Position (kb) P value SNP Position (kb) P value
I rs1808850 10.0 3.49610
27 rs3771365 8.6 1.23610
23
rs1371661 10.7 3.67610
27 rs892515 9.2 3.45610
23
rs4850820 13.6 4.61610
26 rs11681576 9.3 1.21610
22
rs10180112 14.2 4.73610
26 rs7603309 11.1 2.37610
23
rs17792650 12.4 2.47610
23
II rs989056 22.6 3.83610
27 rs11884188 27.6 2.45610
23
rs10168722 33.9 3.77610
27 rs3771367 28.4 2.61610
23
rs1821430 30.6 8.44610
23
rs3771368 32.3 2.32610
22
rs3771369 32.3 2.32610
22
Note: Position (kb) is for the location of a SNP inside intron 5 of the PLCL1 gene, calculated as the distance from the beginning of the intron.
doi:10.1371/journal.pone.0003160.t003
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association with hip BS as shown in Table 2. After the adjustment,
the p values for the SNPs rs7595412, rs4850820, rs10180112, and
rs4850833 were increased to 1.15610
24, 4.85610
24, 4.85610
24,
and 3.03610
24, respectively, as compared to the p values before
the adjustment, which were 3.72610
27, 4.61610
26, 4.73610
26,
and 7.04610
26, respectively. The results suggest that the PLCL1
gene’s association with hip BS may be partially mediated by BMI.
Analyses for potential population stratification
To detect potential stratification of our GWAS sample, we
analyzed our sample using software Structure 2.2 [14]. When
2,000 randomly selected un-linked markers were used to cluster
our subjects, under all assigned values (i.e., 2, 3, or 4) for the
assumed number of population strata, k, all subjects of the sample
were tightly clustered together, suggesting no population stratifi-
cation. The results are shown in Appendix S2.
We further tested our GWAS sample for population stratifica-
tion using the genomic control method [15]. Based on genome-
wide SNP information, we estimated the inflation factor (l), a
measure for population stratification. Ideally, for a homogeneous
population with no stratification, the value of l should be equal or
near to 1.0. In our sample, the estimated l value was 1.007,
suggesting essentially no population stratification and further
confirming the results achieved through the Structure 2.2 software.
We also analyzed the UK replication and Chinese HF samples for
population stratification using the sameapproach described above for
our GWAS sample, and achieved similar results. For the UK cohort,
the subjects under study were those that remained after we excluded
subjects who were not of European ancestry, according to analyses
with Structure 2.2 [14]. The l v a l u ef o rt h eU Ks a m p l ew a s1 . 0 2
according to the genomic control analysis [15]. For the Chinese HF
sample,theStructureprogramshowedthatallsubjectswereclustered
together as a homogeneous population, and a l value of 1.02 was
achieved through analysis with the genomic control method [15].
Other analyses
Using the Q-Q plot, we examined the distribution of p values
achieved in our GWAS for all of the ,380,000 SNPs that were
analyzed (Appendix S3). As shown in the plot, the observed p
values match reasonably well with the expected p values over a
wide range of values of [2LOG10(p)], which is from 0 to ,4.
Observed p values gradually depart from expected p values at the
extreme tail, where [2LOG10(p)] is $,4. The pattern suggests
that our GWAS association findings were more likely due to true
genetic variation than potential bias, such as genotyping errors.
Table 4. Combined imputed p values for SNPs of the PLCL1 gene.
SNP Position Role P value in GWAS P value in UK sample Combined P
rs7595412 198670488 Intron 3 3.74610
27 3.53610
21 2.22610
26
rs1808850 198686906 Intron 5 3.49610
27 3.95610
21 2.31610
26
rs1371661 198687636 Intron 5 3.67610
27 3.97610
21 2.44610
26
rs4850823 198727690 downstream 3.77610
27 4.10610
21 2.58610
26
rs10168722 198710808 Intron 5 3.77610
27 4.12610
21 2.59610
26
rs989056 198699520 Intron 5 3.83610
27 4.12610
21 2.63610
26
rs992603 198735269 downstream 3.77610
27 4.36610
21 2.73610
26
rs12476075 198743194 downstream 3.85610
27 4.53610
21 2.89610
26
rs4850447 198782135 downstream 1.51610
26 8.13610
21 1.80610
25
rs2342753 198781579 downstream 1.58610
26 8.07610
21 1.85610
25
rs10183584 198778210 downstream 2.40610
26 7.50610
21 2.56610
25
rs4850820 198690456 Intron 5 4.61610
26 4.06610
21 2.66610
25
rs10180112 198691103 Intron 5 4.73610
26 4.06610
21 2.72610
25
rs3771367 198705284 Intron 5 4.04610
22 2.61610
23 1.07610
23
rs11884188 198704457 Intron 5 4.84610
22 2.45610
23 1.19610
23
rs11674075 198716751 Intron 5 1.79610
22 7.77610
23 1.37610
23
rs17792650 198689347 Intron 5 6.78610
22 2.47610
23 1.62610
23
rs1821430 198707471 Intron 5 2.69610
22 8.44610
23 2.14610
23
rs3771365 198685530 Intron 5 1.89610
21 1.23610
23 2.17610
23
rs9789480 198755871 downstream 3.14610
21 1.08610
23 3.06610
23
rs1434288 198740743 downstream 8.23610
24 6.30610
21 4.44610
23
rs1304358 198677828 Intron 5 3.29610
21 1.70610
23 4.75610
23
rs7603309 198688008 Intron 5 2.50610
21 2.37610
23 5.00610
23
rs4038716 198738934 downstream 1.88610
22 3.88610
22 5.99610
23
rs892515 198686066 Intron 5 2.80610
21 3.45610
23 7.68610
23
rs1119850 198751505 downstream 5.25610
23 1.88610
21 7.80610
23
rs6434957 198757353 downstream 5.21610
23 1.92610
21 7.91610
23
rs6735486 198757463 downstream 5.21610
23 1.94610
21 7.96610
23
doi:10.1371/journal.pone.0003160.t004
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functions for the identified SNPs as shown in Table 2. According
to the analyses, three SNPs identified in our GWAS sample,
rs7959412, rs4850820 and rs10180112, and a SNP identified in
the UK sample, rs892515, are potential intronic enhancers. A
polymorphic ARG change at rs7959412 and a polymorphic
GRC change at rs4850820 and rs10180112 may eliminate
binding sites for the transcription factors (TFs), GATA-1 and
CdxA, respectively, whereas a polymorphic CRT change at
rs892515 may create a binding site for TFs, GATA-1 and XFD-1.
We compared the results of our GWAS with that of our most
recently performed whole genome linkage study (WGLS) of BS [17].
In our previous WGLS the most significant region linked to hip BS
was 8q24 that achieved a LOD score of 3.27 in the total sample and a
LOD score of 3.01 in the female subgroup. Several genes in that
region also achieved very strong association signals in our current
GWAS. Two SNPs of the ZFAT1 (zinc finger gene in autoimmune
thyroid disease 1) gene, rs7462652 and rs7006328, achieved p values
of 3.71610
25 and 5.03610
25, respectively, for association with hip
BS in the total sample in our GWAS. In addition, three genes,
DEPDC6 (DEP domain containing 6), EIF2C2 (eukaryotic translation
initiation factor 2c, subunit 2) and COLEC10 (collectin 10), eachhad a
SNP (rs9297608, rs2977451 and rs16892015, respectively) associated
with hip BS in the female subjects in our GWAS, with p values of
5.42610
25,5 . 8 6 610
25 and 1.05610
24,r e s p e c t i v e l y .
Discussion
This study represents the first published GWAS for hip BS, an
important risk factor for HF. Through this study we identified a
novel gene, PLCL1 that had four SNPs associated with hip BS at,
or approaching, the genome-wide significance level in our female
subjects. The gene’s association with hip BS was replicated in an
independent UK sample despite it using a different platform and
selection of SNPs. Two SNPs in the UK sample, that are
surrounded by the four interesting SNPs identified in our GWAS,
were associated with hip BS with p values less than 0.01 (Figure 1).
Imputation analyses of our GWAS and the UK samples showed a
significant overlap of association signals in intron 5 of the PLCL1
gene and immediately downstream from that gene (Figure 2). In
particular, according to the imputation analyses, a narrow window
of ,6 kb in intron 5 contained four SNPs that achieved p values
less than 1610
25 (including two of genome-wide significance) in
our GWAS sample, and four SNPs that achieved p values less than
0.01 in the UK sample, (Table 3 and Figure 3). Combining p
values of the imputed SNPs in our GWAS and the UK samples,
we found that eight SNPs of the PLCL1 gene achieved combined p
values less than 10
25, five additional SNPs achieved combined p
values less than 10
24, and fifteen more SNPs achieved combined p
values less than 0.01 (Table 4).
Importantly, we also demonstrated the relevance of PLCL1 to
HF. A SNP of this gene, rs3771362, that is only ,0.6 kb away from
the most significant SNP identified in our GWAS (rs7595412),
achieved a p value of 7.66610
23 and an odds ratio of 0.26 (95% CI:
0.09–0.75) for association with HF in an independent Chinese
sample.PLCL1 encodesan inositol1,4,5-trisphosphate (IP3) binding
protein that can inhibit IP3 mediated calcium signaling [18], an
important pathway that regulates the response of bone cells to
mechanical signals [19,20]. Overall, our association findings,
together with PLCL1’s potential functional relevance to bone
mechanical sensing, provide strong evidence for the gene’s
importance for hip BS variation and the pathogenesis of HF.
In our GWAS sample, the PLCL1 gene’s association with hip BS
was limited only to women, suggesting female-specificity of this
gene’s importance to osteoporosis. The female-specificity of the
gene cannot be determined in the UK replication cohort since the
cohort contains only women but no men [21]. However, analysis
results in the Chinese HF cohort seem to support the female-
specificity of the gene as the gene was associated with HF in
females but not in males (data not shown). Our findings are
consistent with previous studies suggesting that genetic control of
bone parameters may be gender-specific [22–24].
In this study, replication of the PLCL1 gene’s association with
hip BS in the UK sample was achieved ‘‘gene-wise’’ rather than
‘‘SNP-wise’’. The most significant SNPs of the gene detected/
imputed in our GWAS sample did not achieve nominally
significant p values in the UK sample (Table 4), although the
use of different genotyping platforms may be partly responsible.
However, significant replication signals did show up in the UK
sample in many other SNPs of the PLCL1 gene, which are in
neighborhood of those significant SNPs found in the GWAS
sample, according to both the experimental data (Table 2 and
Figure 1) and the imputation data (Table 3 and Figures 2 & 3).
BS can be measured as bone volume (cm
3), bone area (cm
2), or
bone length (or diameter), and each of these measurements is
legitimate and reflects various properties of bone. Areal BS
measured by DXA, as adopted in this study, is a useful and reliable
bone phenotype. Compared with other types of BS measurements,
areal BS is relatively precise and involves less exposure to radiation
during measurement [25,26], enhancing its safety and feasibility
for large-scale clinical investigation. Areal BS is also highly
correlated with bone strength [27] and osteoporotic fractures
[2,28,29], and this correlation is largely independent from BMD
[2,28,29]. Consequently, genetic study of BS may provide a
unique perspective to osteoporosis research, because current
research is largely dominated by studies of BMD.
Population stratification and/or ethnic admixture can be an
important source of spurious association in genetic association
studies. These factors are unlikely to exist in our samples, however,
and are therefore unlikely to interfere with our association results.
The study cohort for our GWAS came from an apparently
homogenous US mid-west white population, living in Omaha,
Nebraska and its surrounding areas. The relative homogeneity of
this population is largely due to the predominance of Caucasians
as the major ethnic group in this area for many generations.
According to the recent 2000 census, ethnic minorities made up
only less than 3% of the entire population in the State of Nebraska.
In addition, we found that the allelic frequencies of the significant
SNPs in our GWAS sample are very similar to those reported in
the typical and representative Caucasian samples used in the
HapMap CEU (Table 2). Furthermore, using Structure 2.2 [14],
we thoroughly analyzed study subjects used in our GWAS in order
to detect potential sub-populations in the sample. In the analyses,
all subjects tightly clustered together as a single group, suggesting
no population substructure in our sample (Appendix S2).
Calculated through the genomic control method [15], the measure
for population stratification (l) for our GWAS sample, was 1.007,
suggesting essentially no stratification. Using the same approaches,
we analyzed the UK replication sample and our Chinese HF
sample and achieved similar results. For the above reasons, the
association results, as detected in our study, are not likely to be
plagued by spurious associations due to population admixture/
stratification. Moreover the wide generalizability of the PLCL1
gene’s association makes this unlikely
In summary, we identified a novel gene, PLCL1, associated with
hip BS through a GWAS. Our success in replicating the
association of this gene with hip BS in a UK sample and the
relevance of this gene to HF in a Chinese cohort, combined with
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cells, makes it a strong candidate for regulation of hip BS and a
potential key factor in the pathogenesis of HF. Apparent female
specificity for the gene’s association with hip BS supports gender-
specific genetic basis of osteoporosis as suggested by previous
studies [23,24] and provides new insights into our understanding
of differential HF risk between females and males. As a future
direction of research, we will perform fine-mapping of the PLCL1
gene in an enlarged independent Caucasian cohort to validate the
gene’s importance to hip BS and HF, including replicating the two
SNPs that showed association with hip BS in the UK cohort
(Table 2). In addition, focused molecular functional studies will be
pursued to clarify the mechanisms by which this gene regulates hip
BS variation and contributes to HF risk. The gene may also be
related to bone growth in general – which also merits further work.
Materials and Methods
Subjects
The study was approved by the required Institutional Review
Boards of all involved Institutions. Signed informed-consent
documents were obtained from all study participants before they
entered the study.
For the GWAS, a random sample containing 1,000 unrelated
participants, including 501 women and 499 men, was identified from
our established and expandinggenetic repertoire currently containing
more than 6000 subjects. All of the subjects were US Caucasians of
European origin. Individuals with chronic diseases and conditions
that might potentially affect bone metabolism were excluded. These
diseases/conditions included chronic disorders involving vital organs
(heart, lung, liver, kidney, brain), serious metabolic diseases (diabetes,
hypo- and hyper-parathyroidism, hyperthyroidism, etc.), other
skeletal diseases (paget disease, osteogenesis imperfecta, rheumatoid
arthritis, etc.), chronic use of drugs affecting bone metabolism
(hormone replacement therapy, corticosteroid therapy, anti-convul-
sant drugs), malnutrition conditions (such as chronic diarrhea,
chronic ulcerative colitis, etc.), etc. Subjects taking anti-bone-
resorptive or bone anabolic agents/drugs, such as bisphosphonates,
were also excluded from this study. The purpose of the above
exclusion criteria was to minimize the effects of environmental and
therapeutic factors thought or known to influence the skeletal system
and so improve power and ability to find genes.,
For our GWAS sample, areal BS values of total hip (proximal
femur) were measured using dual energy X-ray absorptiometry
(DXA) machines (Hologic Inc., Bedford, MA, USA) that were
calibrated daily. The coefficients of variation (CV) of the DXA
measurements for BS were about 1.94%. General relevant
characteristics of the study subjects are presented in Table 1.
For replication of the PLCL1 gene’s association with hip BS, an
independent sample containing 1,216 women of Caucasian
European ancestry from the UK were used. The sample was
selected from the TwinsUK cohort (www.twinsuk.ac.uk), a
population-based sample of Britons previously shown to be
representative of singleton populations, and the United Kingdom
population, in general [30]. The areal BS of total hip site (proximal
femur) was measured by DXA machines (Hologic Inc, Bedford,
MA) using standard protocols. Basic characteristics of the UK
study subjects are presented in Table 1.
To validate the relevance of the PLCL1 gene to HF, we used a
Chinese sample containing 403 female subjects including 226 with
low trauma osteoporotic HF and 177 controls. All subjects were
unrelated northern Chinese Han adults living in the city of Xi’an
and its neighboring areas. Affected individuals with low trauma
HF were recruited from the affiliated hospitals and associated
clinics of Xi’an Jiaotong University. Inclusion criteria for HF
patients were (i) age ,80 years and onset age .55 years (all
subjects were postmenopausal); (ii) HF caused by minimal or no
trauma, usually due to falls from standing height or less; (iii)
fracture site at the femoral neck or inter-trochanter regions; (iv)
HF was identified/confirmed through diagnosis of orthopedic
surgeons/radiologists according to radiological reports and x-rays.
Patients with pathological fractures (e.g. due to tumors) and high-
impact fractures (e.g. due to motor vehicle accidents) were
excluded. Control subjects were enrolled through local advertise-
ments. They were geography- and age-matched to the patients. All
controls were older than 55 years, postmenopausal, and had no
fracture history. Additional exclusion criteria for the control
subjects were the same as those for our GWAS sample. The basic
characteristics of the Chinese study subjects are shown in Table 1.
Genotyping
GWAS sample. Genomic DNA was extracted from whole
human blood using a commercial isolation kit (Gentra systems,
Minneapolis, MN, USA) following protocols detailed in the kit.
Genotyping with the Affymetrix Mapping 250 k Nsp and Affymetrix
Mapping 250 k Sty arrays was performed in Vanderbilt Microarray
Shared Resources (VMSR) (http://array.mc.vanderbilt.edu/) using
the standard protocol recommended by Affymetrix. Genotyping calls
were determined from the fluorescent intensities using the DM
algorithm with a 0.33 P- v a l u es e t t i n g[ 3 1 ]a sw e l la st h eB - R L M M
algorithm [32]. DM calls were used for quality control while the B-
RLMM calls were used for all subsequent data analysis. B-RLMM
clustering was performed with 94 samples per cluster.
The final average BRLMM call rate across the entire sample
reached the high level of 99.14%. However, out of the initial full-
set of 500,568 SNPs, we discarded 32,961 SNPs with sample call
rates ,95%, another 36,965 SNPs with allele frequencies
deviating from Hardy-Weinberg equilibrium (HWE) (p,0.001),
and 51,323 SNPs with minor allele frequencies (MAF) ,1%.
Therefore, the final SNP set maintained in the subsequent analyses
contained 379,319 SNPs, yielding an average marker spacing of
,7.9 kb throughout the human genome.
UK replication sample. Subjects in the UK sample were
genotyped with the Illumina Infinium assay across three genome-
wide SNP sets, using fully compatible SNP arrays (Hap300 Duo,
Hap300 and Hap550). Strict quality control criteria were applied,
resulting in exclusion of 2,605 SNPs for violating Hardy-Weinberg
equilibrium (p,10
24), 8,866 SNPs for low call rate (,90%), and
710 SNPs for low MAF (,0.01); 306,823 SNPs were retained for
final association analyses.
Chinese HF sample. Subjects in the Chinese sample were
genotyped with the Affymetrix Human Mapping 500 K array set
(Affymetrix, Santa Clara, CA) following the same protocol used for
our GWAS sample.
Quality control procedures were as follows. First, only samples
with a minimum of 95% call rate were included; the final mean
BRLMM call rate of the entire sample reached a high level of
99.02%. Second, out of the initial full set of 500,568 SNPs, we
discarded: 1) SNPs with a call rate ,90% in both cases and
controls (n=54,845); 2) those deviating from Hardy-Weinberg
equilibrium (HWE) in controls (p,0.001, n=22,002); 3) those
having a minor allele frequency (MAF) ,0.05 in the total sample
(n=142,188). Therefore, 281,533 SNPs were eventually available
for subsequent association analyses.
Statistical Analyses
GWAS sample. Parameters including age, age
2, height and
weight were tested for their association with hip BS. Significant
GWAS of Hip Bone Size
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BS values for subsequent analyses. The adjusted BS data, if not
following normal distributions, were further subjected to BoxCox
transformation into normal distribution. GWAS analyses were
performed through genotypic association tests implemented in
HelixTree 5.3.1 (Golden Helix, Bozeman, MT, USA). This
commercial program incorporates the well known genetic analyses
programs, FBAT and PBAT (http://www.biostat.harvard.edu/
,fbat/default.html), and the associated statistical methods [33].
The genome-wide significance threshold was set at
p=4.2610
27, derived by Freimer and Sabatti [34] based on a
gene-wise approach, and subsequently modified by Lencz et al.
[35] taking into account a more accurate estimate of the total
number of genes in the human genome.
UK replication sample. Raw hip BS values were adjusted
through the same procedures, described above, for the GWAS
sample. Association analyses were performed using the PLINK
(QFAM) software package (version 1.01) (http://pngu.mgh.
harvard.edu/purcell/plink/) accounting for family structure in
the sample [36]. Some of the subjects are monozygotic twins, and
for these sib-pairs, genotypic information for only one individual
per pair was included in the analyses, since monozygotic twins
share identical genetic information. Where a single dizygotic twin
had missing data, or was excluded, the remaining sibling was
treated as a singleton in the statistical analysis.
Chinese HF sample. Association analyses for the SNPs of
the PLCL1 gene were performed using the PLINK software
package (version 1.02) [36]. Odds ratio for the SNP rs3771362 was
calculated using logistic regression as implemented in Minitab
package (Minitab Inc., State College, PA).
Quality control analyses. To detect population
stratification in our GWAS sample, which may lead to spurious
association results, we used the software Structure 2.2 (http://
pritch.bsd.uchicago.edu/software.html) to investigate the potential
substructure of our sample. The program uses a Markov chain
Monte Carlo (MCMC) algorithm to cluster individuals into
different cryptic sub-populations on the basis of multi-locus
genotype data [14]. To ensure robustness of our results, we
performed independent analyses under three assumed numbers for
population strata (k=2, 3, and 4), using 2,000 un-linked markers
that were randomly selected across the entire genome. To confirm
the results achieved through Structure 2.2, we further tested
population stratification of our GWAS sample using a method of
genomic control [15].
To investigate if the association findings in our GWAS were due
to potential bias (e.g., genotyping error), we examined the
distribution of p values for all ,380,000 SNPs analyzed in our
sample using the quantile-quantile (Q-Q) plot.
The program, Structure 2.2 [14], and the method of genomic
control [15] were also applied to the UK replication sample and
the Chinese HF sample to test for potential population
stratification.
Other analyses. The SNPs of the PLCL1 gene genotyped in
our GWAS sample were largely different from that genotyped in
the UK replication sample due to different genotyping platforms
used for the two samples. In order to better compare association
signals between the two samples at the region of this gene, we
imputed a set of dense SNP markers common to both samples
(HapMap data, NCBI Build 35) that cover the entire region based
on the markers genotyped in the respective samples. To impute
the genotypes of un-typed SNPs, we used the software IMPUTE
[37] (http://www.stats.ox.ac.uk/,marchini/software/gwas/
impute.html). Based on the imputed genotypes, we performed
single SNP association analyses using the software SNPTEST
(http://www.stats.ox.ac.uk/,marchini/software/gwas/snptest.
html) to impute p values of un-typed SNPs. To quantify the overall
significance of imputed association signals in both our GWAS and
the UK samples, Fisher’s method [12] was used to combine the
individual p values imputed in each of the two samples.
To explore potential functions of the interesting SNPs identified
in our GWAS and the UK replication samples, we used the
FASTSNP (function analysis and selection tool for SNPs) program
(http://fastsnp.ibms.sinica.edu.tw) that analyzes SNP functions
based on up-to-date information extracted from 11 external
bioinformatic databases at query time [16].
Supporting Information
Appendix S1 The most significant 30 SNPs for hip BS detected
in GWAS. Note: SNP A-1819962* does not have a dbSNP ID.
The ID as shown in the table is an Affy ID.
Found at: doi:10.1371/journal.pone.0003160.s001 (0.11 MB
DOC)
Appendix S2 Results of analyses of potential population
stratification for the GWAS sample using Structure 2.2. Note:
As shown is output of the software Structure 2.2, which clustered
our study subjects using 2,000 randomly selected unlinked markers
under three assumed numbers of population strata, k=2, 3, 4.
Found at: doi:10.1371/journal.pone.0003160.s002 (0.04 MB TIF)
Appendix S3 Q-Q plots for the p values achieved in the GWAS
Found at: doi:10.1371/journal.pone.0003160.s003 (0.05 MB TIF)
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